#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Diffuse large B-cell lymphoma Vulval cancer recurrent Cardiomyopathy PIK3CA related overgrowth spectrum Chronic myeloid leukaemia Bronchiolitis Mucopolysaccharidosis III Follicular lymphoma Penile squamous cell carcinoma B-cell lymphoma refractory Endometrial cancer recurrent Herpes simplex Metabolic disorder Anaplastic thyroid cancer Hepatic cirrhosis More trials…

    Learn about Rare Diseases

    Factor IX deficiency – Basic Information Cytokine release syndrome Alexander disease Niemann-Pick disease Ewing’s sarcoma metastatic Leiomyosarcoma recurrent – Basic Information Ocular melanoma – Diagnostics Lennox-Gastaut syndrome – Basic Information Lennox-Gastaut syndrome Haemophilia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    F44/10 Chlorphenamine Maleate Clebopride Hydrogen Maleate Nandrolone Decanoate Necvax-Neo1 GSKVX000000034797 Oxybutynin Solrikitug Dobutamine Cetirizine Dihydrochloride Brivaracetam Vusolimogene Oderparepvec Mrna-4157 RO7268489 ABBV-8736 Holcus Lanatus Pollen Extract Tigulixostat MORPHINE SGN-ALPV IADADEMSTAT More therapies…

    Learn about Your Condition

    Cognitive disorder Deafness traumatic Vitamin D deficiency Lichenoid keratosis Radicular pain Mantle cell lymphoma stage III Myotonic dystrophy Diabetic retinopathy Naevus flammeus Depression Arteriospasm coronary Methylmalonic acidaemia Toxic nodular goitre Frostbite Chronic lymphocytic leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Frisius

Frisius

Henri Dunantweg 2, Heerenveen, 8934 AD, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell cancer of the renal pelvis and ureter
    • Transitional cell carcinoma urethra
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    • Carboplatin
    • Cisplatin
    Belgium Czechia Denmark France Germany Hungary +4

  • Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Belgium Ireland Italy The Netherlands Portugal Spain

  • Study comparing FOLFIRINOX versus gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    Investigated Drugs:
    • Folinic Acid
    • Irinotecan Hydrochloride Trihydrate
    • Fluorouracil
    The Netherlands

  • Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Decitabine
    • Midostaurin
    Belgium The Netherlands

  • Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • 1,3-BUTYLENE GLYCOL
    • Brentuximab Vedotin
    • Cinchocaine Hydrochloride
    Belgium Denmark The Netherlands Poland Portugal Slovakia +1

  • Study on Liposomal Irinotecan, Carboplatin, or Oxaliplatin for First-Line Treatment in Patients with Advanced Esophagogastric Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Fluorouracil
    The Netherlands

  • Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Cardiac failure
    • Cardiac failure acute
    • Cardiac failure chronic
    Investigated Drugs:
    • Cdr132L
    • Cdr132L Sodium
    Czechia Germany Greece Hungary The Netherlands Poland +1

  • Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma stage II
    • Mantle cell lymphoma stage III
    • Mantle cell lymphoma stage IV
    Investigated Drugs:
    • Ibrutinib
    Belgium Czechia Denmark Finland Germany Italy +6

  • Study of Tiragolumab and Atezolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    Austria Germany Greece Hungary Italy The Netherlands +2
Previous Page
1 … 10 11 12

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!